Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
Status:
Recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
The Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation (EVENT) was designed
to examine the hypothesis that, compared with placebo, therapy with the SGLT2 inhibitor
enavogliflozin would improve clinical and echocardiographic outcomes in heart failure (HF)
patients with functional tricuspid regurgitation (TR) and preserved left ventricular ejection
fraction (LVEF).
The primary objective of the EVENT study is to test the hypothesis that, compared with
placebo, therapy with enavogliflozin for 18 months would improve a composite of
cardiovascular events or worsening of TR on follow-up echocardiography in HF patients with
functional TR and preserved LVEF. The secondary objective is to examine whether
enavogliflozin is effective in reduction of renal events and tricuspid regurgitation, and to
evaluate whether beneficial effects of enavogliflozin on primary outcomes are associated with
reduction of all-cause mortality.